SKBI [SKYSTAR BIO-PHARMACEUTICAL] 8-K: (Original Filing)
[LETTER FROM PREDECESSOR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM 100 F Street, NE Dear Ladies and Gentlemen: Brea,lifornia January 7, 2010 LETTER FROM MSWFT v170753_ex16-1.htm 2 EX-16.1]
SKBI [SKYSTAR BIO-PHARMACEUTICAL] 8-K: LETTER FROM PREDECESSOR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
[LETTER FROM PREDECESSOR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM 100 F Street, NE Dear Ladies and Gentlemen: Brea,lifornia January 7, 2010 LETTER FROM MSWFT v170753_ex16-1.htm 2 EX-16.1]
EGT [Entertainment Gaming Asia] 8-K: (Original Filing)
[CONTACTS: Elixir Gaming Traci Mangini SVP, Corporate Finance 312/867-0848 ELIXIR GAMING TECHNOLOGIES ANNOUNCES PARTICIPATION CONSOLIDATION - New Agreement Includes Expanded Operations and Favorable Consolidated Contract Terms - Elixir Gaming in Final Stages of Asset Valuation Analysis and Anticipates Recording Hong Kong January 6, 2010 - Elixir Gaming Technologies, Inc. (NYSE Amex: EGT) (Elixir Gaming or the Company), a] [ELIXIR GAMING TECHNOLOGIES, INC. Nevada 001-32161 91-1696010 (State or Other Jurisdiction of (I.R.S. Employer Identification Unit 3705, 37/F, The Centrium 60 Wyndham Street Central, Hong Kong + 852-3151-3800 Unit 2B, 29/F, The Centrium 60 Wyndham Street Central, Hong Kong (Former name or former address, if changed since last report) o o o]
EGT [Entertainment Gaming Asia] 8-K: CONTACTS: Elixir Gaming Traci Mangini SVP, Corporate Finance
[CONTACTS: Elixir Gaming Traci Mangini SVP, Corporate Finance 312/867-0848 ELIXIR GAMING TECHNOLOGIES ANNOUNCES PARTICIPATION CONSOLIDATION - New Agreement Includes Expanded Operations and Favorable Consolidated Contract Terms - Elixir Gaming in Final Stages of Asset Valuation Analysis and Anticipates Recording Hong Kong January 6, 2010 - Elixir Gaming Technologies, Inc. (NYSE Amex: EGT) (Elixir Gaming or the Company), a] [ELIXIR GAMING TECHNOLOGIES, INC. Nevada 001-32161 91-1696010 (State or Other Jurisdiction of (I.R.S. Employer Identification Unit 3705, 37/F, The Centrium 60 Wyndham Street Central, Hong Kong + 852-3151-3800 Unit 2B, 29/F, The Centrium 60 Wyndham Street Central, Hong Kong (Former name or former address, if changed since last report) o o o]
BSPM [Biostar Pharmaceuticals,] 8-K: BIOSTAR PHARMACEUTICALS, INC. CODE OF ETHICS Dated: December
[BIOSTAR PHARMACEUTICALS, INC. CODE OF ETHICS Dated: December 30, 2009 POLICY STATEMENT Code Company · honest and ethical conduct, including the ethical handling of actual or apparent conflicts of interest between personal and professional relationships; · SEC · compliance with applicable governmental laws, rules, and regulations; · the prompt internal reporting to the appropriate person of violations of this Code;] [BIOSTAR PHARMACEUTICALS, INC. To: [Director Name] [Address] Dear [Director Name]: Company This is to confirm the terms of your appointment as a Non-Executive Director and as [_____] of Biostar Pharmaceuticals, Inc. (the “ Board Overall, in terms of time commitment, we expect your attendance at all the Board of Directors (the " By accepting this appointment, you have confirmed that] [Biostar Pharmaceuticals Strengthens Corporate Governance with Appointments of New Independent Directors, Establishment of Board Committees and Adoption of Code of Ethics Xi’an, China – January 4, 2010 – , today announced a series of measures adopted to strengthen the Company’s corporate governance in compliance with the listing requirements of a senior U.S. exchange. December 30, 2009. First, two directors, Mr.]
BSPM [Biostar Pharmaceuticals,] 8-K: (Original Filing)
[BIOSTAR PHARMACEUTICALS, INC. CODE OF ETHICS Dated: December 30, 2009 POLICY STATEMENT Code Company · honest and ethical conduct, including the ethical handling of actual or apparent conflicts of interest between personal and professional relationships; · SEC · compliance with applicable governmental laws, rules, and regulations; · the prompt internal reporting to the appropriate person of violations of this Code;] [BIOSTAR PHARMACEUTICALS, INC. To: [Director Name] [Address] Dear [Director Name]: Company This is to confirm the terms of your appointment as a Non-Executive Director and as [_____] of Biostar Pharmaceuticals, Inc. (the “ Board Overall, in terms of time commitment, we expect your attendance at all the Board of Directors (the " By accepting this appointment, you have confirmed that] [Biostar Pharmaceuticals Strengthens Corporate Governance with Appointments of New Independent Directors, Establishment of Board Committees and Adoption of Code of Ethics Xi’an, China – January 4, 2010 – , today announced a series of measures adopted to strengthen the Company’s corporate governance in compliance with the listing requirements of a senior U.S. exchange. December 30, 2009. First, two directors, Mr.]
BSPM [Biostar Pharmaceuticals,] 8-K: BIOSTAR PHARMACEUTICALS,DE OF ETHICSted:December 30, 2009 POLICY STATEMENTdempany
[BIOSTAR PHARMACEUTICALS,DE OF ETHICSted:December 30, 2009 POLICY STATEMENTdempany honest and ethicalnduct,luding the ethical handling of actual or apparentnflicts of interest between personal and professional relationships; SECmpliance with applicable governmental laws, rules, and regulations; the prompt internal reporting to the appropriate person of violations of thisde; and] [BIOSTAR PHARMACEUTICALS, To: [Director Name] [Address] Dear [Director Name]:mpany This is tonfirm the terms of your appointment a Non-Executive Director and [_____] of Biostar Pharmaceuticals, (the Board Overall, in terms of timemmitment, we expect your attendance atl the Board of Directors (the "] [Biostar Pharmaceuticals Strengthensrporate Governance with Appointments of New Independent Directors, Establishment of Boardmmittees andoption ofde of Ethics Xian, China January 4, 2010 , today announced a series of measuresopted to strengthen thempanysrporate governance inmpliance with the listing requirements of a senior U.S. exchange.]
BSPM [Biostar Pharmaceuticals,] 8-K: (Original Filing)
[BIOSTAR PHARMACEUTICALS,DE OF ETHICSted:December 30, 2009 POLICY STATEMENTdempany honest and ethicalnduct,luding the ethical handling of actual or apparentnflicts of interest between personal and professional relationships; SECmpliance with applicable governmental laws, rules, and regulations; the prompt internal reporting to the appropriate person of violations of thisde; and] [BIOSTAR PHARMACEUTICALS, To: [Director Name] [Address] Dear [Director Name]:mpany This is tonfirm the terms of your appointment a Non-Executive Director and [_____] of Biostar Pharmaceuticals, (the Board Overall, in terms of timemmitment, we expect your attendance atl the Board of Directors (the "] [Biostar Pharmaceuticals Strengthensrporate Governance with Appointments of New Independent Directors, Establishment of Boardmmittees andoption ofde of Ethics Xian, China January 4, 2010 , today announced a series of measuresopted to strengthen thempanysrporate governance inmpliance with the listing requirements of a senior U.S. exchange.]
BSPM [Biostar Pharmaceuticals,] 8-K: (Original Filing)
[Biostar Pharmaceuticals, Inc. to Launch Xin Aoxing Oleanolic Acid Capsules in Beijing and Shanghai Management anticipates $9 million in 2010 revenues from this initiative XIANYANG, China, December 29, 2009 (Xinhua-PRNewswire-FirstCall) Management anticipates approximately $9 million in incremental revenues during 2010 from these two new markets with average gross margins of approximately 72%. Biostar launched its marketing and operational initiatives for]
BSPM [Biostar Pharmaceuticals,] 8-K: Biostar Pharmaceuticals, Inc. to Launch Xin Aoxing Oleanolic
[Biostar Pharmaceuticals, Inc. to Launch Xin Aoxing Oleanolic Acid Capsules in Beijing and Shanghai Management anticipates $9 million in 2010 revenues from this initiative XIANYANG, China, December 29, 2009 (Xinhua-PRNewswire-FirstCall) Management anticipates approximately $9 million in incremental revenues during 2010 from these two new markets with average gross margins of approximately 72%. Biostar launched its marketing and operational initiatives for]
